Stereotaxis Receives Regulatory Approval of e-Contact™ Module in Canada

Stereotaxis, Inc., the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced that it has received regulatory clearance from Health Canada for its e-Contact™ Module, which provides physicians with a simple-to-interpret indicator of catheter tip-to-tissue contact. The technology was launched in Europe in June and to date has been utilized in more than 1,300 robotic catheter ablation procedures.

The e-Contact Module is Stereotaxis’ latest innovation designed to improve patient outcomes, reduce procedure times, and advance automation. Dr. Eugene Crystal, Director of Arrhythmia Services at Sunnybrook Health Sciences Centre in Toronto, and president elect of SCRN, performed the first procedures with the e-Contact module in North America during the week of November 20.

“The latest Stereotaxis innovation adds to the Niobe^® system’s inherent advantages by providing the ability to accurately determine catheter-to-tissue contact at the point of interest,” said Dr. Crystal. “This feature has the capability to further improve robotic magnetic navigation outcomes and efficiency in complex ablation procedures like AF and VT by ensuring first-pass, complete, durable linear lesions.”

Sunnybrook has been a leader in utilizing Stereotaxis technology for a broad range of arrhythmias, becoming Toronto’s first robotic arrhythmia lab with installation of the Niobe magnetic navigation system in 2010. Sunnybrook performs an estimated 70 percent of its arrhythmia ablation cases with Stereotaxis robotic technology.

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.